---
document_datetime: 2023-09-21 18:25:50
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/fablyn-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: fablyn-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.0712278
conversion_datetime: 2025-12-22 08:04:39.051687
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

Telephone +44 (0)20 7418 8400 Facsimile +44 (0) 20 7523 7455 Fablyn Procedural steps taken and scientific information after the authorisation 1 Notifications are issued for type I variations (unless part of a group or a worksharing application). Opinions are issued for all other procedures. 2 No Commission Decision is issued for type IA and type IB variations or for type II variations and annual re-assessments that do not affect the annexes. 3 SPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). Medicinal product no longer authorised

<!-- image -->

| No        | Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3 longer   | Summary                                                                                             |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|-----------------------------------------|-----------------------------------------------------------------------------------------------------|
| T/0003    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 22/12/2011                          | 17/02/2012                                  | SPC, Labelling, PL                      | Transfer of the Marketing Authorisation from Pfizer Ltd. to Dr. Friedrich Eberth Arzneimittel GmbH. |
| IG/0044/G | This was an application for a group of variations. C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD, C.I.9.g - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the site undertaking pharmacovigilance activities, C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the | 02/03/2011 product                  | n/a no                                      |                                         |                                                                                                     |

7 Westferry Circus

●

Canary Wharf

●

London E14 4HB

●

United Kingdom

E-mail

info@ema.europa.eu Website www.ema.europa.eu

<!-- image -->

<div style=\"page-break-after: always\"></div>

| No      | Scope                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                |
|---------|------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0001 | pharmacovigilance system Update of DDPS (Pharmacovigilance) Update of DDPS (Pharmacovigilance) | 25/06/2009                          | 24/07/2009                                  | Annex II                         | The Detailed Description of the Pharmacovigilance System (DDPS) has been updated (version 2.0) in order to reflect various organisational changes as well as the change of the global safety database. Consequently, Annex II has been updated using the standard text including the new version number of the agreed DDPS. authorised |

Medicinal product no longer authorised